Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2020-03 phase 2a study in agitation associated with Alzheimer's disease dementia
jRCT2031240641Phase 2Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ONO-2020 with Placebo (2 arms). Primary endpoint: Change in CMAI score from baseline to Week 12. Started May 2025; status: recruiting.
02
Drugs
ONO-2020
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031240641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240641.